RxDoctor Payments Data

David Barker, MD

Obstetrics & Gynecology · Chattanooga, TNNPI 1104801216

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations.

$4,024in general payments, 2019–2025

Across 220 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$429
  • AbbVie$335
  • Sumitomo Pharma America, Inc.$322
  • Myovant Sciences Inc.$300
  • Astellas Pharma US Inc$293
  • Bayer$265
  • plus $2K from 36 others
$442,378in research payments, 2019–2025

Across 62 payments — averaging $7135.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Organon$293K
  • Dexcom, Inc.$106K
  • Teva Pharmaceuticals USA, Inc.$41K
  • GSK$2K

What the payments were for

  • Food & beverage$4,00099%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,024 in reported general payments places this provider in the 80th percentile of 763 obstetrics & gynecology providers in Tennessee.

See all obstetrics & gynecology providers in Tennessee

Medicare billing

Part B allowed, 2024
$18,317
Medicare patients
116
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol12$516
Clobetasol Propionate15$487
ValacyclovirValacyclovir Hcl13$399

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →